Rapid Micro Biosystems (NASDAQ:RPID) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Rapid Micro Biosystems' stock has received a "sell (D-)" rating from Weiss Ratings, with an average rating of "Moderate Buy" and a consensus target price of $8.00.
• The company reported a loss of ($0.27) earnings per share for the last quarter, missing the consensus estimate, while also achieving revenue of $7.26 million.
• Insider transactions indicate CEO Robert G. Jr. Spignesi sold 11,881 shares, decreasing his ownership stake, while institutional investors hold 52.60% of the company's stock.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report)'s stock had its "sell (d-)" rating reiterated by research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other research firms have also recently weighed in on RPID. Wall Street Zen upgraded Rapid Micro Biosystems from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Lake Street Capital began coverage on Rapid Micro Biosystems in a report on Monday, July 28th. They set a "buy" rating and a $8.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $8.00.

Rapid Micro Biosystems Stock Down 5.1%

Shares of NASDAQ:RPID opened at $3.50 on Wednesday. The business has a fifty day moving average of $3.02 and a two-hundred day moving average of $3.03. The stock has a market cap of $154.74 million, a P/E ratio of -3.47 and a beta of 1.38. Rapid Micro Biosystems has a 52-week low of $0.83 and a 52-week high of $4.50.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.01). The company had revenue of $7.26 million during the quarter, compared to analysts' expectations of $7.10 million. Rapid Micro Biosystems had a negative net margin of 145.63% and a negative return on equity of 63.07%. Rapid Micro Biosystems has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Rapid Micro Biosystems will post -1.1 earnings per share for the current year.

Insider Transactions at Rapid Micro Biosystems

In other Rapid Micro Biosystems news, CEO Robert G. Jr. Spignesi sold 11,881 shares of the stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $3.32, for a total value of $39,444.92. Following the sale, the chief executive officer owned 970,550 shares of the company's stock, valued at $3,222,226. This trade represents a 1.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 29.96% of the company's stock.

Institutional Investors Weigh In On Rapid Micro Biosystems

A number of hedge funds have recently bought and sold shares of RPID. Millennium Management LLC raised its position in Rapid Micro Biosystems by 17.6% in the 4th quarter. Millennium Management LLC now owns 61,375 shares of the company's stock valued at $55,000 after purchasing an additional 9,191 shares in the last quarter. Legato Capital Management LLC acquired a new stake in Rapid Micro Biosystems in the 1st quarter valued at about $41,000. Essex Investment Management Co. LLC acquired a new stake in Rapid Micro Biosystems in the 1st quarter valued at about $166,000. Evernest Financial Advisors LLC acquired a new stake in shares of Rapid Micro Biosystems during the 1st quarter worth about $347,000. Finally, Informed Momentum Co LLC acquired a new stake in shares of Rapid Micro Biosystems during the 1st quarter worth about $467,000. Institutional investors and hedge funds own 52.60% of the company's stock.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems, Inc, a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.